Reuters
01 Sept 2026, 06:20 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
1 claim · each scored for market impact
AstraZeneca's late-stage trial in China showed that combining Tagrisso and Orpathys significantly improved progression-free survival as a first-line lung cancer treatment. — Positive clinical trial results for high-value oncology drugs typically drive stock price increases and expand future market share.
+0.60Which stocks this story touches
Positive results from a late-stage trial for a cancer drug combination show significantly improved progression-free survival.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
1h ago
